Clinical Trial Detail

NCT ID NCT03544125
Title Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors OHSU Knight Cancer Institute
Indications

triple-receptor negative breast cancer

Therapies

Durvalumab + Olaparib

Age Groups: senior adult

No variant requirements are available.